297 related articles for article (PubMed ID: 28662680)
1. Systematic review of patient reported quality of life following stereotactic ablative radiotherapy for primary and metastatic liver cancer.
Mutsaers A; Greenspoon J; Walker-Dilks C; Swaminath A
Radiat Oncol; 2017 Jun; 12(1):110. PubMed ID: 28662680
[TBL] [Abstract][Full Text] [Related]
2. Prospective Longitudinal Assessment of Quality of Life for Liver Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Klein J; Dawson LA; Jiang H; Kim J; Dinniwell R; Brierley J; Wong R; Lockwood G; Ringash J
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):16-25. PubMed ID: 26279020
[TBL] [Abstract][Full Text] [Related]
3. Quality of life changes after stereotactic ablative radiotherapy for liver metastases: A prospective cohort analysis.
Helou J; Thibault I; Chu W; Munoz-Schuffenegger P; Erler D; Rodrigues G; Warner A; Chan KKW; Chow E; Korol R; Davidson M; Chung HT
Radiother Oncol; 2018 Dec; 129(3):435-440. PubMed ID: 30274721
[TBL] [Abstract][Full Text] [Related]
4. Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer: A Systematic Review.
Chen H; Louie AV; Boldt RG; Rodrigues GB; Palma DA; Senan S
Clin Lung Cancer; 2016 Sep; 17(5):e141-e149. PubMed ID: 26791542
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma.
Takeda A; Sanuki N; Eriguchi T; Kobayashi T; Iwabutchi S; Matsunaga K; Mizuno T; Yashiro K; Nisimura S; Kunieda E
J Gastroenterol Hepatol; 2014 Feb; 29(2):372-9. PubMed ID: 23927053
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiation Therapy Compared With Surgery and Radiofrequency Ablation in Two Patient Cohorts: Metastatic Liver Cancer and Hepatocellular Carcinoma.
Jin H; Chalkidou A; Hawkins M; Summers J; Eddy S; Peacock JL; Coker B; Kartha MR; Good J; Pennington M;
Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):e143-e154. PubMed ID: 32951952
[TBL] [Abstract][Full Text] [Related]
7. Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMET.
Olson R; Abraham H; Leclerc C; Benny A; Baker S; Matthews Q; Chng N; Bergman A; Mou B; Dunne EM; Schellenberg D; Jiang W; Chan E; Atrchian S; Lefresne S; Carolan H; Valev B; Tyldesley S; Bang A; Berrang T; Clark H; Hsu F; Louie AV; Warner A; Palma DA; Howell D; Barry A; Dawson L; Grendarova P; Walker D; Sinha R; Tsai J; Bahig H; Thibault I; Koul R; Senthi S; Phillips I; Grose D; Kelly P; Armstrong J; McDermott R; Johnstone C; Vasan S; Aherne N; Harrow S; Liu M
BMC Cancer; 2024 Feb; 24(1):171. PubMed ID: 38310262
[TBL] [Abstract][Full Text] [Related]
8. Quality of Life Outcomes After Stereotactic Ablative Radiation Therapy (SABR) Versus Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial.
Olson R; Senan S; Harrow S; Gaede S; Louie A; Haasbeek C; Mulroy L; Lock M; Rodrigues G; Yaremko B; Schellenberg D; Ahmad B; Griffioen G; Senthi S; Swaminath A; Kopek N; Liu M; Moore K; Currie S; Bauman G; Warner A; Palma D
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):943-947. PubMed ID: 31470091
[TBL] [Abstract][Full Text] [Related]
9. Prospective Longitudinal Assessment of Quality of Life After Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-based SABR-5 Phase II Trial.
Cruz-Lim EM; Mou B; Baker S; Arbour G; Stefanyk K; Jiang W; Liu M; Bergman A; Schellenberg D; Alexander A; Berrang T; Bang A; Chng N; Matthews Q; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson R
Clin Oncol (R Coll Radiol); 2024 Mar; 36(3):148-156. PubMed ID: 38087705
[TBL] [Abstract][Full Text] [Related]
10. Repeated stereotactic ablative radiotherapy using CyberKnife for patients with hepatocellular carcinoma.
Lo CH; Huang WY; Lin KT; Lin MJ; Lin TP; Jen YM
J Gastroenterol Hepatol; 2014 Nov; 29(11):1919-25. PubMed ID: 25041220
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic ablative radiation therapy prior to liver transplantation in hepatocellular carcinoma.
Guarneri A; Franco P; Romagnoli R; Trino E; Mirabella S; Molinaro L; Rizza G; Filippi AR; Carucci P; Salizzoni M; Ricardi U
Radiol Med; 2016 Nov; 121(11):873-881. PubMed ID: 27447803
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported Quality of Life following Stereotactic Body Radiation Therapy for Primary Kidney Cancer - Results from a Prospective Cohort Study.
Swaminath A; Cheung P; Glicksman RM; Donovan EK; Niglas M; Vesprini D; Kapoor A; Erler D; Chu W
Clin Oncol (R Coll Radiol); 2021 Jul; 33(7):468-475. PubMed ID: 33775496
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Quality of Life Decline in Patients with Oligometastases treated with Stereotactic Ablative Radiotherapy: Analysis of the Population-Based SABR-5 Phase II Trial.
Cruz-Lim EM; Mou B; Jiang W; Liu M; Bergman A; Schellenberg D; Alexander A; Berrang T; Bang A; Chng N; Matthews Q; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson R; Baker S
Clin Oncol (R Coll Radiol); 2024 Mar; 36(3):141-147. PubMed ID: 38296662
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer.
Hannan R; Christensen M; Christie A; Garant A; Pedrosa I; Robles L; Mannala S; Wang C; Hammers H; Arafat W; Courtney K; Bowman IA; Sher D; Ahn C; Cole S; Choy H; Timmerman R; Brugarolas J
Eur Urol Oncol; 2022 Dec; 5(6):695-703. PubMed ID: 35985982
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer.
Lagerwaard FJ; Aaronson NK; Gundy CM; Haasbeek CJ; Slotman BJ; Senan S
J Thorac Oncol; 2012 Jul; 7(7):1148-54. PubMed ID: 22610256
[TBL] [Abstract][Full Text] [Related]
17. Safety and Effectiveness of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Lesions: A Systematic Review.
Chen H; Laba JM; Zayed S; Boldt RG; Palma DA; Louie AV
J Thorac Oncol; 2019 Aug; 14(8):1332-1342. PubMed ID: 31075543
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S
BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760
[TBL] [Abstract][Full Text] [Related]
19. Threshold doses for focal liver reaction after stereotactic ablative body radiation therapy for small hepatocellular carcinoma depend on liver function: evaluation on magnetic resonance imaging with Gd-EOB-DTPA.
Sanuki N; Takeda A; Oku Y; Eriguchi T; Nishimura S; Aoki Y; Mizuno T; Iwabuchi S; Kunieda E
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):306-11. PubMed ID: 24411601
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Survival Analysis of Stereotactic Ablative Radiotherapy Versus Liver Resection for Small Hepatocellular Carcinoma.
Su TS; Liang P; Liang J; Lu HZ; Jiang HY; Cheng T; Huang Y; Tang Y; Deng X
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(3):639-646. PubMed ID: 28581406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
